Mabpharm Ltd
HKEX:2181
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Mabpharm Ltd
HKEX:2181
|
CN |
|
G
|
Gielda Papierow Wartosciowych w Warszawie SA
WSE:GPW
|
PL |
|
S
|
SPEL Semiconductor Ltd
BSE:517166
|
IN |
Mabpharm Ltd
Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2019-05-31. The firm's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The firm mainly conducts its businesses in China market.
Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2019-05-31. The firm's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The firm mainly conducts its businesses in China market.